Results of a cohort model analysis of the cost-effectiveness of routine immunization with 13-valent pneumococcal conjugate vaccine of those aged > or =65 years in the Netherlands.

@article{Rozenbaum2010ResultsOA,
  title={Results of a cohort model analysis of the cost-effectiveness of routine immunization with 13-valent pneumococcal conjugate vaccine of those aged > or =65 years in the Netherlands.},
  author={Mark Hermannes Rozenbaum and Eelko Hak and Tjip S. van der Werf and Maarten J Postma},
  journal={Clinical therapeutics},
  year={2010},
  volume={32 8},
  pages={1517-32}
}
BACKGROUND Community-acquired pneumonia and invasive pneumococcal disease are common among older people (ie, those aged > or =65 years). A new 13-valent pneumococcal conjugate vaccine (PCV-13) is under study in the Netherlands. OBJECTIVE The aim of this work was to model the cost-effectiveness of PCV-13 vaccination among those aged > or =65 years in the… CONTINUE READING